The Medicines Company to Participate in RBC Capital Markets' Healthcare Conference

(firmenpresse) - PARSIPPANY, NJ -- (Marketwire) -- 02/22/13 -- The Medicines Company (NASDAQ: MDCO) will present at the 2013 RBC Capital Markets' Healthcare Conference on Tuesday, February 26 in a question and answer session from 09:30 to 09:55 am.

The session will be webcast with a link available at The Medicines Company's website .

The Medicines Company (NASDAQ: MDCO) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients. The Medicines Company's website is .





Contact:
Michael Mitchell
The Medicines Company
973-290-6000

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 22.02.2013 - 21:41 Uhr
Sprache: Deutsch
News-ID 232452
Anzahl Zeichen: 0

contact information:
Town:

PARSIPPANY, NJ

Kategorie:

Healthcare

Diese Pressemitteilung wurde bisher 177 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"The Medicines Company to Participate in RBC Capital Markets' Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

The Medicines Company (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

The Medicines Company to Participate in Upcoming Investor Conference Webcasts ...

PARSIPPANY, NJ -- (Marketwired) -- 11/27/13 -- The Medicines Company (NASDAQ: MDCO) is scheduled to present at the 25th Annual Piper Jaffray Healthcare Conference on December 4th at 12:30 PM Eastern Time. MDCO is also scheduled to present at the Opp ...

European Medicines Agency Accepts Marketing Authorization Application for The Me ...

PARSIPPANY, NJ -- (Marketwired) -- 11/21/13 -- The Medicines Company (NASDAQ: MDCO) today announced that the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for the investigational hemostatic agent ...

FDA Grants QIDP Designation to The Medicines Company's Investigational Anti ...

PARSIPPANY, NJ -- (Marketwired) -- 11/12/13 -- The Medicines Company (NASDAQ: MDCO) today announced that the U.S. Food and Drug Administration (FDA) has designated oritavancin as a Qualified Infectious Disease Product (QIDP). The QIDP designation pr ...

Alle Meldungen von The Medicines Company